The PACMAN-AMI trial was recently published in JAMA
05.04.2022 - The results of the PACMAN-AMI randomized controlled trial were recently published in the Journal of the American Medical Association. The trial compared the addition of a lipid-lowering drug (Alirocumab, a PCSK9 inhibitor) to high-intensity statin therapy on lipid plaque development in coronary arteries of patients with acute myocardial infarction.
Across 300 patients, serial intracoronary imaging showed that the combination of Alirocumab and statin therapy provided greater reductions in percent atheroma volume and lipid burden, as well as a greater increase in minimal fibrous cap thickness compared with statin therapy alone, through a year of treatment. Reduction in percent atheroma volume and lipid burden as well as increase in minimal fibrous cap thickness reflect positive changes in patient lipid plaque. The trial is helping us to understand how lipid-lowering therapy can improve clinical outcomes.
For further reading:
- The publication: https://jamanetwork.com/journals/jama/fullarticle/2790913
- A press release of ACC 2022: https://www.tctmd.com/news/pacman-ami-positive-plaque-changes-early-alirocumab-use-acute-mi